Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells $750,619.98 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the transaction, the executive vice president owned 63,647 shares in the company, valued at approximately $2,247,375.57. The trade was a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Christine Fox also recently made the following trade(s):

• On Thursday, March 5th, Christine Fox sold 7,924 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $31.67, for a total transaction of $250,953.08.

Teva Pharmaceutical Industries Stock Up 1.4%

TEVA opened at $36.36 on Thursday. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The stock has a market cap of $41.81 billion, a price-to-earnings ratio of 27.34, a PEG ratio of 3.47 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35. The company’s 50-day moving average price is $31.24 and its two-hundred day moving average price is $29.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. As a group, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Piper Sandler reiterated an “overweight” rating and issued a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Scotiabank boosted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Finally, Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Global Retirement Partners LLC increased its holdings in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after acquiring an additional 292 shares during the period. Captrust Financial Advisors increased its holdings in Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock worth $459,000 after acquiring an additional 302 shares during the period. Banque Cantonale Vaudoise increased its holdings in Teva Pharmaceutical Industries by 6.3% during the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after acquiring an additional 306 shares during the period. Ethic Inc. increased its holdings in Teva Pharmaceutical Industries by 1.8% during the 4th quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after acquiring an additional 325 shares during the period. Finally, Allworth Financial LP increased its holdings in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the period. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.